HEPATITIS VACCINE MARKET ANALYSIS

Regional Analysis

Regional Dynamics

On the basis of regions, hepatitis vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the hepatitis vaccine market, owing to high healthcare spending and availability of robust healthcare infrastructure in the region. According to Centre for Disease Control (CDC) data in 2016, the U.S. had 0.6 cases per 1, 00,000 population. Even though this rate of incidence is low as compared to regions such as Asia Pacific and Africa, still due to highest healthcare spending by U.S. population hepatitis vaccine North America is lucrative market for hepatitis vaccine market. Asia Pacific has greatest burden of hepatitis (154 million people with hepatitis B) currently as mentioned in World Hepatitis Report, 2017 and it is attractive market for hepatitis market due to the larger population getting infected from the hepatitis. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected.